Abstral® is a rapidly disintegrating sublingual tablet for management of breakthrough cancer pain in patients already being treated with opioids. The product contains the pain-relieving substance fentanyl. Abstral® allows doses to be customized according to individual requirements, which is essential for achieving optimal pain relief.